Form 4: Veracyte Director Evan Jones Sells Shares Under 10b5-1 Plan

Director Evan Jones sold 5,173 shares of Veracyte (VCYT) common stock on September 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 19, 2024, Evan Jones, a director of Veracyte, Inc. (VCYT), sold 5,173 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on February 28, 2024.
• The shares were sold at a weighted average price of $35.2335, with individual sale prices ranging from $35.085 to $35.43.
• Following the transaction, Jones directly owns no shares but indirectly owns 34,343 shares through jVen Capital, LLC, where he is the sole managing member.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The use of a 10b5-1 plan suggests the sale was pre-planned and doesn't necessarily reflect a negative outlook on the company.

Industry Context

Sales by insiders are a normal part of corporate activity. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific inside information at the time of the transaction.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates